Sirolimus for epileptic seizures associated with focal cortical dysplasia type II

OBJECTIVE: To determine whether sirolimus, a mechanistic target of rapamycin (mTOR) inhibitor, reduces epileptic seizures associated with focal cortical dysplasia (FCD) type II. METHODS: Sixteen patients (aged 6–57 years) with FCD type II received sirolimus at an initial dose of 1 or 2 mg/day based...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Mitsuhiro, Kada, Akiko, Shiraishi, Hideaki, Tohyama, Jun, Nakagawa, Eiji, Takahashi, Yukitoshi, Akiyama, Tomoyuki, Kakita, Akiyoshi, Miyake, Noriko, Fujita, Atsushi, Saito, Akiko M., Inoue, Yushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862414/
https://www.ncbi.nlm.nih.gov/pubmed/35040598
http://dx.doi.org/10.1002/acn3.51505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862414/
https://www.ncbi.nlm.nih.gov/pubmed/35040598
http://dx.doi.org/10.1002/acn3.51505

Ejemplares similares